| 000 | 01478 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250512063743.0 | ||
| 264 | 0 | _c19871106 | |
| 008 | 198711s 0 0 eng d | ||
| 022 | _a0006-3223 | ||
| 024 | 7 |
_a10.1016/0006-3223(87)90049-7 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHollander, E | |
| 245 | 0 | 0 |
_aRS 86 in the treatment of Alzheimer's disease: cognitive and biological effects. _h[electronic resource] |
| 260 |
_bBiological psychiatry _cSep 1987 |
||
| 300 |
_a1067-78 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Controlled Clinical Trial; Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAlzheimer Disease _xdrug therapy |
| 650 | 0 | 4 |
_aCognition _xdrug effects |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEvoked Potentials, Auditory _xdrug effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHydrocortisone _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aParasympathomimetics _xadverse effects |
| 650 | 0 | 4 | _aRandom Allocation |
| 650 | 0 | 4 |
_aSuccinimides _xadverse effects |
| 700 | 1 | _aDavidson, M | |
| 700 | 1 | _aMohs, R C | |
| 700 | 1 | _aHorvath, T B | |
| 700 | 1 | _aDavis, B M | |
| 700 | 1 | _aZemishlany, Z | |
| 700 | 1 | _aDavis, K L | |
| 773 | 0 |
_tBiological psychiatry _gvol. 22 _gno. 9 _gp. 1067-78 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/0006-3223(87)90049-7 _zAvailable from publisher's website |
| 999 |
_c3657231 _d3657231 |
||